<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04776343</url>
  </required_header>
  <id_info>
    <org_study_id>2020_06_02</org_study_id>
    <nct_id>NCT04776343</nct_id>
  </id_info>
  <brief_title>Study Comparing Two Populations of Patients Treated With Anti VEGF for Diabetic Macular Edema, One Being Followed at the Hospital and the Other One Being Followed at Home Using a Software Allowing Self-assessment of Visual Acuity</brief_title>
  <official_title>Prospective, Randomized Study Comparing Two Populations of Patients Treated With Anti VEGF for Diabetic Macular Edema, One Being Followed at the Hospital and the Other One Being Followed at Home Using a Software Allowing Self-assessment of Visual Acuity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital St. Joseph, Marseille, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital St. Joseph, Marseille, France</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Verify the reliability of VA measured every week at home, by the patient using a TC, compared&#xD;
      to the reliability of VA also measured by the patient using a TC but every 2 month at the&#xD;
      hospital, during standard DME follow-up visits&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients with VA evolution in the two groups</measure>
    <time_frame>36 months</time_frame>
    <description>rate in percentage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variation of the VA measured using ETDRS scale on TC for the patients followed at home</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of the VA measured using ETDRS scale on TC for the patients followed at the hospital</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of follow-up and injection visits for each patient according to their group</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average time between the follow-up visit and the IVT (if performed)</measure>
    <time_frame>36 months</time_frame>
    <description>in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variations in foveolar thickness and maximum central retinal thickness on OCT</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life for patients in group 1 compared to group 2</measure>
    <time_frame>36 months</time_frame>
    <description>the quality of life is assessed with EQ-5D-5L questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the total cost per patient for patient in group 1 compared to group 2.</measure>
    <time_frame>36 months</time_frame>
    <description>The total cost per patient is calculated from the number of follow-up visits, the number of procedures (OCT and fundus retinography) and the number of IVTs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Telemedecine follow-up</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hospital follow-up</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>telemedecine follow-up</intervention_name>
    <description>weekly home-based follow-up of visual acuity on electronic tablet</description>
    <arm_group_label>Telemedecine follow-up</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Will be included in the study, patients with all of the following criteria:&#xD;
&#xD;
          -  aged ≥ 25 years old (the minimum age is set at 25 years old in order to include&#xD;
             patient with controlled diabetes);&#xD;
&#xD;
          -  diagnosed with DME;&#xD;
&#xD;
          -  followed and treated by anti-VEGF IVT in the ophthalmology debarment at Hopital Saint&#xD;
             Joseph Marseille;&#xD;
&#xD;
          -  having a VA score ≥ 20/100;&#xD;
&#xD;
          -  able to understand the study and to use a TC;&#xD;
&#xD;
          -  having an internet access at home;&#xD;
&#xD;
          -  having given free and informed written consent;&#xD;
&#xD;
          -  being affiliated with or benefiting from a social security scheme.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Will not be included in the study, patients with one of the following criteria:&#xD;
&#xD;
          -  treated for another pathology that DME;&#xD;
&#xD;
          -  already participating to another research study;&#xD;
&#xD;
          -  pregnant or breastfeeding woman;&#xD;
&#xD;
          -  subject to a measure for the protection of justice.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cecile Bielmann</last_name>
    <phone>0033 (0)4 88 73 10 70</phone>
    <email>cbielmann@hopital-saint-joseph.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Saint Joseph Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Cécile Bielmann</last_name>
    </contact>
    <investigator>
      <last_name>Frédéric Queguiner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

